Brokerages Set Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Price Target at $570.83

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has received a consensus recommendation of “Moderate Buy” from the twenty-three research firms that are currently covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating, twenty have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $573.8261.

A number of equities research analysts have commented on the company. Sanford C. Bernstein upgraded Vertex Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, July 29th. Cantor Fitzgerald upped their target price on Vertex Pharmaceuticals from $590.00 to $595.00 and gave the company an “overweight” rating in a report on Tuesday, August 4th. The Goldman Sachs Group set a $653.00 price target on shares of Vertex Pharmaceuticals in a report on Tuesday, September 1st. Leerink Partners began coverage on shares of Vertex Pharmaceuticals in a research note on Monday. They issued an “outperform” rating and a $594.00 price objective on the stock. Finally, Stifel Nicolaus set a $500.00 price objective on shares of Vertex Pharmaceuticals in a research report on Tuesday, August 4th.

Key Headlines Impacting Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Positive Phase 2b inaxaplin results: Vertex reported favorable results from the AMPLIFIED study in additional patient groups, including people with APOL1-mediated kidney disease and modest proteinuria and those with the disease and type 2 diabetes. The data support inaxaplin’s potential to address a broader patient population and strengthen Vertex’s kidney-disease pipeline. Vertex Announces Positive Results From Phase 2b AMPLIFIED Study
• Positive Sentiment: Late-stage trial enrollment completed: Vertex also announced completion of enrollment in the Phase 2/3 AMPLITUDE trial of inaxaplin. This reduces a key development uncertainty and moves the program closer to potentially pivotal efficacy results and eventual regulatory filings. Vertex Touts Encouraging Data From Underappreciated Kidney Drug
• Positive Sentiment: Analyst support adds to the catalyst: Leerink Partners initiated coverage with an “outperform” rating and a $594 price target, implying additional upside from the referenced share price. The endorsement reinforces confidence in Vertex’s pipeline and inaxaplin’s commercial potential. Vertex Pharmaceuticals Analyst Coverage
• Neutral Sentiment: Investor attention is elevated: Vertex was identified as a trending stock, while broader coverage highlighted increasing investment and competition in chronic kidney disease treatments. These reports may increase visibility but do not provide a new fundamental catalyst beyond the clinical announcement. Vertex Is a Trending Stock
• Negative Sentiment: Vertex had experienced some premarket weakness earlier in the news cycle, but that pressure appears secondary to the stronger reaction to the inaxaplin data. Vertex Pharma Stock Slips Premarket

Insider Transactions at Vertex Pharmaceuticals

In other news, CMO Carmen Bozic sold 596 shares of the business’s stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $482.50, for a total value of $287,570.00. Following the transaction, the chief marketing officer directly owned 15,337 shares of the company’s stock, valued at $7,400,102.50. The trade was a 3.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Duncan McKechnie sold 1,541 shares of the firm’s stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $519.00, for a total value of $799,779.00. Following the sale, the executive vice president directly owned 11,001 shares of the company’s stock, valued at $5,709,519. This represents a 12.29% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 3,637 shares of company stock valued at $1,874,834. Corporate insiders own 0.20% of the company’s stock.

Institutional Investors Weigh In On Vertex Pharmaceuticals

A number of large investors have recently bought and sold shares of the stock. BlackRock Inc. bought a new position in shares of Vertex Pharmaceuticals in the 2nd quarter worth $11,975,849,000. Norges Bank acquired a new position in Vertex Pharmaceuticals during the fourth quarter worth $1,440,149,000. Bank of America Corp DE bought a new position in shares of Vertex Pharmaceuticals in the second quarter valued at $1,509,651,000. Legal & General Group Plc bought a new position in shares of Vertex Pharmaceuticals in the second quarter valued at $928,893,000. Finally, Bank of New York Mellon Corp acquired a new position in shares of Vertex Pharmaceuticals during the second quarter valued at about $830,842,000. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Vertex Pharmaceuticals Price Performance

NASDAQ:VRTX opened at $514.99 on Friday. Vertex Pharmaceuticals has a one year low of $374.17 and a one year high of $560.25. The firm’s 50 day simple moving average is $513.19 and its 200 day simple moving average is $474.59. The company has a market cap of $130.70 billion, a PE ratio of 29.98, a P/E/G ratio of 2.24 and a beta of 0.32.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Monday, August 3rd. The pharmaceutical company reported $4.73 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.74 by ($0.01). The business had revenue of $3.33 billion for the quarter, compared to the consensus estimate of $3.23 billion. Vertex Pharmaceuticals had a net margin of 35.00% and a return on equity of 23.09%. Vertex Pharmaceuticals’s revenue was up 12.5% on a year-over-year basis. During the same period in the previous year, the business posted $4.52 EPS. Equities research analysts expect that Vertex Pharmaceuticals will post 16.69 EPS for the current year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company combines research in human genetics with drug discovery and development.

Vertex is best known for its cystic fibrosis portfolio, which includes CFTR modulator therapies such as Kalydeco, Orkambi, Symdeko and the combination marketed as Trikafta in the United States and Kaftrio in other markets.